

# Lymphatic Filariasis

**Source: PIB** 

#### Why in News?

Recently, the Union Health Minister inaugurated the **second phase of the** <u>Annual Nationwide Mass Drug Administration (MDA) initiative</u> **for** <u>Lymphatic Filariasis.</u>

 India aims to eliminate Lymphatic Filariasis by 2027, three years ahead of the global target, through a mission-driven strategy.

## What is Lymphatic Filariasis?

- About:
  - Lymphatic filariasis, commonly known as elephantiasis, is a neglected tropical disease caused by parasitic infection which is transmitted through the bite of infected mosquitoes.
  - This impacts millions of individuals in tropical and subtropical regions across the globe.
- Causes and Transmission:
  - Lymphatic filariasis is caused by infection with parasites classified as nematodes (roundworms) of the family Filariodidea.
  - There are 3 types of these thread-like filarial worms:
    - Wuchereria bancrofti, which is responsible for 90% of the cases,
    - Brugia malayi, which causes most of the remainder of the cases,
    - Brugia timori, which also causes the disease.
- Symptoms:
  - Lymphatic filariasis infection involves asymptomatic, acute, and chronic conditions.
    - In chronic conditions, it leads to lymphoedema (tissue swelling) or elephantiasis (skin/tissue thickening) of limbs and hydrocele (scrotal swelling).
- Treatment:
  - The World Health Organization (WHO) recommends three drug treatments to accelerate the global elimination of lymphatic filariasis. The treatment, known as IDA, involves a combination of ivermectin, diethylcarbamazine citrate and albendazole.
    - The plan is to administer these drugs for two consecutive years. The life of the adult worm is hardly four years, so it would die a natural death without causing any harm to the person.
- Global Threat and Preventive Measures:
  - Over 882 million people in 44 countries face the threat of lymphatic filariasis and require preventive chemotherapy.
  - Preventive measures involve **mass drug administration (MDA)** to the at-risk population using safe medicine combinations.
  - More than 9 billion treatments have been administered since 2000 to halt infection spread.
- Progress and Achievements:
  - Successful MDA efforts have reduced transmission and infection prevalence.

- 740 million people no longer require preventive chemotherapy.
- In 2018, 51 million people were infected, marking a 74% reduction since the initiation of global elimination efforts.

### Vector Control and WHO's Approach:

- Mosquito control, such as insecticide-treated nets and indoor residual spraying, supplements preventive chemotherapy.
- WHO's **Global Programme to Eliminate Lymphatic Filariasis (GPELF)** launched in 2000 with a mission to eradicate the disease.
  - GPELF aims to validate elimination in 80% of endemic countries by achieving sustained low infection rates and providing care.
  - The program strives for post-MDA surveillance in all endemic countries and ultimately reduces the population needing MDA to zero.
- The strategy focuses on stopping infection spread and providing essential care to affected individuals.

## What are India's Initiatives for Lymphatic Filariasis Eradication?

- Nationwide Mass Drug Administration campaigns administer preventive medicines in endemic areas.
- Collaboration with various stakeholders, sectors, and NGOs enhances the initiative's impact.
- "Through Jan Bhagidaari and 'Whole of Government' and 'Whole of Society' approach, India shall be able to eliminate this disease from the country".
- Second phase of the MDA initiative targets 81 districts in 9 endemic states for targeted intervention. (Assam, Bihar, Chhattisgarh, Jharkhand, Karnataka, Maharashtra, Odisha, Telangana and Uttar Pradesh).
- State-central collaborations enhance healthcare, surveillance, prevention, and treatment.
- Encouraging medication consumption in the presence of healthcare workers promotes adherence.

PDF Refernece URL: https://www.drishtiias.com/printpdf/lymphatic-filariasis-2